Regulation FD Disclosure. On November 4, 2026, the Company issued a press release announcing the License Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. On November 4, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. On November 4, 2026, the Company made available a presentation to be used in meetings wit…

Entry into a Material Definitive Agreement. Hinova Pharmaceuticals Inc. License Transaction License Agreement On November 4, 2026, Evommune, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Hinova Pharmaceuticals Inc., a company incorporated in the People’s Republic of China (“Hinova”). Pursuant to the License Agreement and subject to certain rights retained by Hinova, Hinova granted the Company the exclusive and sublicensable rights to develop,…

Based in part upon the representations of Hinova in the Licensing Agreement and the Warrants, the offering and sale of the Licensing Securities will be exempt from registration under Rule 903 of Regulation S promulgated under the Securities Act. The Licensing Securities have not been registered under the Securities Act or any state securities laws, and the Licensing Securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the…

Other Events. Based upon preliminary estimates and information available to the Company, it estimates that the gross proceeds from the Private Placement before deducting placement agent fees and commissions, together with its cash, cash equivalents, and investments as of September 30, 2026, will be approximately $292.3 million following the closing of the Private Placement, and will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the second hal…

Other Events. On September 8, 2026, the Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe Atopic Dermatitis (“AD”). The Phase 2b trial enrolled 121 adults with moderate-to-severe AD over a 12-week treatment period, with follow-up through Week 14. The trial did not meet the primary and secondary endp…

Results of Operations and Financial Condition. On August 6, 2026, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the second quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Secti…

Other Events. On June 29, 2026, the Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (“CSU”). The Phase 2b trial enrolled 160 moderate-to-severe antihistamine-refractory CSU patients in the United States, Europe, Canada and Japan. Participants received one of three act…

Results of Operations and Financial Condition. On May 7, 2026, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the first quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section…

Results of Operations and Financial Condition. On March 5, 2026, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the three months and full year ended December 31, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for pu…

The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each of the Investors has provided representations appropriate for a private placement of securities. The sale of the Shares did not involve a public offering and was made without general solicitation or general advertising. Neither this Current Report on Form 8-K nor any exhibit attached here…

Regulation FD Disclosure. On February 12, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The…

Entry into a Material Definitive Agreement. On February 12, 2026, Evommune, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of 4,494,279 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). Each Share was offered and sold at…

Results of Operations and Financial Condition. On December 11, 2025, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the third quarter ended September 30, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes o…